{"preliminary_commentary":{"by_channel":{"x_thread":9,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03739814\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["inotuzumab ozogamicin","blinatumomab"],["inotuzumab ozogamicin","blinatumomab","ponatinib"]],"indication":"CD22-positive B-cell acute lymphoblastic leukemia","name":"A041703","nct_id":"NCT03739814","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=a041703-nct03739814. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"See Detailed Description..","label":"Cohort 1 (inotuzumab ozogamicin, blinatumomab)","type":"EXPERIMENTAL"},{"description":"See Detailed Description.","label":"Cohort 2 (inotuzumab ozogamicin, blinatumomab)","type":"EXPERIMENTAL"},{"description":"See detailed description","label":"Cohort 3 (inotuzumab ozogamicin, blinatumomab, ponatinib))","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-02-01","type":"ESTIMATED"},"conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","Recurrent B Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia"],"enrollment":{"count":84,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Blinatumomab","otherNames":["AMG 103","AMG-103","AMG103","Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody","Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103","Blincyto","MEDI 538","MEDI-538","MEDI538","MT 103","MT-103","MT103"],"type":"BIOLOGICAL"},{"name":"Bone Marrow Aspiration","otherNames":[],"type":"PROCEDURE"},{"name":"Bone Marrow Biopsy","otherNames":["Biopsy of Bone Marrow","Biopsy, Bone Marrow"],"type":"PROCEDURE"},{"name":"Inotuzumab Ozogamicin","otherNames":["Besponsa","CMC 544","CMC-544","CMC544","Way 207294","WAY-207294"],"type":"BIOLOGICAL"},{"name":"Lumbar Puncture","otherNames":["LP","Spinal Tap"],"type":"PROCEDURE"},{"name":"Ponatinib","otherNames":["AP 24534","AP-24534","AP24534"],"type":"DRUG"}],"last_update":"2026-10-28","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-02-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event-free survival","timeFrame":"At 1 year"},{"measure":"Completion of protocol treatment (cohort 3)","timeFrame":"Up to 10 years"}],"references":[{"citation":"Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067.","pmid":"41671463","type":"DERIVED"},{"citation":"Wieduwilt MJ, Yin J, Kour O, Teske R, Stock W, Escherich C, Yang J, Li Z, Byrd K, Doucette K, Mangan J, Hall S, Mims AS, Jamieson K, Dinner SN, Bseiso AW, Giordano G, Saygin C, Uy GL, Litzow MR, Stone RM. Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. J Clin Oncol. 2025 Nov 10;43(32):3526-3535. doi: 10.1200/JCO-25-00307. Epub 2025 Sep 30.","pmid":"41026957","type":"DERIVED"},{"citation":"Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704.","pmid":"35622074","type":"DERIVED"}],"start_date":{"date":"2019-05-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia","url":"https://clinicaltrials.gov/study/NCT03739814"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/a041703-nct03739814"}